Among these new targets, ICOS, 4-1BB, and With different potential targets, including PD-1/PD-L1, CTLA-4, Tim-3, inducibleĬostimulator (ICOS), 4-1BB, and OX-40. Numerous immunomodulatory therapies are being investigated in various clinical trials Finally,Īrticles were revised and the information processed according to the GRADE system Įvidence was classified, and recommendations were then posed according to the The first author was contacted to obtain those articles, in which theįinal version was not available online, and thus, no information was lost. Updated collection of scientific evidence.Īll authors performed the revision and extraction of data from the original Published in the past 15 years and in English were included to ensure the most “monoclonal antibodies,” “therapeutic target,” and “immunotherapy.” Only articles T-lymphocyte-associated protein 4 (CTLA-4),” “PD-1,” “PD-L1,” “immunocheckpoint,” The search was conducted using the MEDLINE and the PubMed databaseīrowsers combining the following terms: “CC,” cancer,” “cytotoxic Patient, intervention, control, and outcome acronym question was used to detectĪrticles, including checkpoint inhibitors, immunotherapy treatment, PD1, PD-L1,ĬTL-4, and CC. Pathways through different monoclonal antibodies to disrupt immunologic tolerance as In this review, we present the current data aimed to targeting PD-1, PD-L1, and CTL-4 Immunotherapy is currently being tested for CC in different clinical trials toĪddress its effectiveness and tolerability in second-line therapies. Inhibitors, especially programmed cell death-1/programmed cell death ligand-1įavorable efficacy results for the treatment of multiple solid tumors such as lungĪnd kidney cancer, among others 8. In this regard, the introduction of immune checkpoint Several approaches have been tested in the last decade aimed to improve OS inĭifferent neoplasms. The lack of an effective second-line treatment remains the main cause of the high Nevertheless, in patients who progress during first-line treatment, The standard treatment in these clinical stages 6. To 17 months in recurrent, persistent or metastatic CC, and is currently considered Improved progression-free survival (PFS) from 6 months to 8.2 months and OS from 13 In 2014, based on the results of the Gynecologic Oncology Group (GOG)Ģ40 trial, it was concluded that the addition of bevacizumab to CT with doublets Most of these patients can only be treated with palliativeĬhemotherapy (CT), based on cisplatin doublets 5. This poor prognosis is mainly due to limited treatment options 4. However, 5-year OS for recurrent, persistent, or metastatic CC is only a mere 15%. Surgery or concomitant chemoradiotherapy 3. Survival (OS) can reach approximately 75-85% with effective treatments such as Locally advanced stages (IB2-IVA) and metastatic IVB stage. More than 80% of cases of CC are diagnosed at Key words: Immunotherapy Cytotoxic T-lymphocyte-associated protein 4 Programmed cell death-1/Programmed cell death ligand-1 Checkpoint Monoclonal antibodiesĬervical cancer (CC) remains an important public health problem in Mexico 1 since it ranks second in terms of morbidityĪnd is one of the leading causes of death in women of reproductive age 2. Well as on trials that are still in the recruitment phase, to confirm their Review, we will focus on the usefulness of these PD-1/PDL1 inhibitors in CC, as There are also some ongoing trials that could provide furtherĮvidence on the PD-1/PD-L1 pathway as a therapeutic target in CC. PD-1/PD-L1 inhibitors in recurrent, persistent, or metastatic CC, as second-line Phase I/II clinical trials that have assessed the usefulness of pembrolizumabĪnd nivolumab in this group of patients these include the KEYNOTE 028, KEYNOTEġ58, and CHECKMATE 358 trials, in which clinical benefit has been proven with Improve clinical outcomes in this group of patients. (PD-1/PD-L1) inhibitors could be a novel and cutting-edge therapeutic option to Patients with recurrent, persistent, or metastatic cervical CC, theĮffectiveness of treatment is limited, except for the combination ofĬhemotherapy based on platinum doublets plus bevacizumab, the treatment that hasĪchieved the best results to date. With concomitant chemoradiotherapy in locally advanced stages. Of patients in early stages are cured of the disease with surgical treatment and Important health problem, especially in developing countries. Cervical cancer (CC) is one of the most common gynecological tumors and an
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |